And then everyone panic sells, page-54

Hey D

Did a quick skim search on some MSB. U guys may be across or maybe not seen but anyway have fun.

Some links below in order of first one then clicked an identifier link to another page then same for another.

One of the descriptions in the first link sounded like MSB stuff plus scientific review due Nov 18, so followed the trail till saw Revascor to confirm appears linked to your studies.

Shows who's running it etc by looks and u guys can sift through if any other leads / info u find interesting.

First https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-19-009.html

4. Circulatory Assist Devices and Cardiac Regeneration: The Network has built expertise in conducting stem cell trials in LVAD patients, and could conduct a follow-up trial of the nearly-completed LVAD MPC II Trial (NCT02362646), or expand our portfolio by evaluating new biologicals, such as cardiosphere-derived cells, exosomes, or human embryonic stem cells derived from cardiomyocytes. Optimizing outcomes in patients receiving circulatory support alone remains an important goal. A randomized trial of a constellation (“bundle” of management strategies versus standard therapy to reduce complications in LVAD patients is under consideration. Finally, cardiogenic shock remains a high-mortality condition, and the Network investigators are exploring trials of both ECMO and percutaneous VADs to improve the fate of this patient population.

Second https://clinicaltrials.gov/ct2/show/NCT02362646?term=Mesenchymal cells and Gelijns&rank=1

Clicked the clinical id.

Third https://clinicaltrials.gov/ct2/show/NCT02362646

Biological: MPC Intramyocardial Injection
Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
Other Names:

• Mesenchymal Precursor Cell Injection
• RevascorTM